DaVita (DVA) 주식 개요
는 미국에서 만성 신부전으로 고통받는 환자들을 위한 신장 투석 서비스를 제공합니다. 자세히 보기
DVA Community Fair Values
Create NarrativeSee what 45 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
DaVita Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$236.31 |
| 52주 최고가 | US$239.64 |
| 52주 최저가 | US$101.00 |
| 베타 | 0.88 |
| 1개월 변동 | 8.88% |
| 3개월 변동 | 57.47% |
| 1년 변동 | 62.62% |
| 3년 변동 | 131.70% |
| 5년 변동 | 94.70% |
| IPO 이후 변동 | 5,699.00% |
최근 뉴스 및 업데이트
Seeking Alpha • Jul 25
Davita: Valuation Is Nearing Resistance Level
Summary Davita currently trades near the upper end of its historical valuation channel. Valuation levels suggest DVA may be approaching overvalued territory relative to its historical norms. Investors should monitor for potential mean reversion if DVA's valuation remains elevated. This positioning may warrant caution or profit-taking for those with existing positions. Read the full article on Seeking Alpha
내러티브 업데이트 • Jul 15
DVA: AI Kidney Care Platform Will Drive Future Earnings Repricing
Analysts have lifted the DaVita fair value estimate from $179.66 to $270.00, citing a series of higher price targets up to $270 and research that highlights sector tailwinds, ongoing growth investments, and company specific initiatives around advanced dialysis technologies, GLP-1 use, and home care services. Analyst Commentary Recent research updates around DaVita point to a more constructive tone, with several bullish analysts revising their fair value views higher and emphasizing the potential impact of company execution on advanced dialysis technologies, GLP-1 integration, and home care efforts.
내러티브 업데이트 • Jun 30
DVA: Future Margin Assumptions And GLP-1 Headwinds May Restrain Upside
DaVita's updated analyst price target has shifted to $145 from $126, reflecting analysts' revised assumptions for lower discount rates, different revenue growth expectations, higher profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research on DaVita points to a mixed set of views, with some analysts revising price targets and ratings based on updated assumptions around discount rates, revenue growth, margins, and valuation multiples.Recent updates
Seeking Alpha • Jul 25
Davita: Valuation Is Nearing Resistance Level
Summary Davita currently trades near the upper end of its historical valuation channel. Valuation levels suggest DVA may be approaching overvalued territory relative to its historical norms. Investors should monitor for potential mean reversion if DVA's valuation remains elevated. This positioning may warrant caution or profit-taking for those with existing positions. Read the full article on Seeking Alpha내러티브 업데이트 • Jul 15
DVA: AI Kidney Care Platform Will Drive Future Earnings Repricing
Analysts have lifted the DaVita fair value estimate from $179.66 to $270.00, citing a series of higher price targets up to $270 and research that highlights sector tailwinds, ongoing growth investments, and company specific initiatives around advanced dialysis technologies, GLP-1 use, and home care services. Analyst Commentary Recent research updates around DaVita point to a more constructive tone, with several bullish analysts revising their fair value views higher and emphasizing the potential impact of company execution on advanced dialysis technologies, GLP-1 integration, and home care efforts.내러티브 업데이트 • Jun 30
DVA: Future Margin Assumptions And GLP-1 Headwinds May Restrain Upside
DaVita's updated analyst price target has shifted to $145 from $126, reflecting analysts' revised assumptions for lower discount rates, different revenue growth expectations, higher profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research on DaVita points to a mixed set of views, with some analysts revising price targets and ratings based on updated assumptions around discount rates, revenue growth, margins, and valuation multiples.
내러티브 업데이트 • Jun 16
DVA: Share Repurchases And GLP-1 Risks Will Shape Future Stock Economics
DaVita's analyst price target has been raised by $57, with analysts citing updated assumptions around discount rates, long term revenue growth, profit margin, and future P/E as key drivers of the revised valuation view. Analyst Commentary Recent research on DaVita highlights a cluster of upward price target revisions and an upgrade, with analysts revisiting their assumptions on discount rates, long term revenue growth, profit margins, and future P/E multiples.내러티브 업데이트 • Jun 02
DVA: Share Repurchases And GLP-1 Headwinds Will Shape Future Kidney Care Economics
DaVita’s updated analyst price target holds steady at $193.71, with recent upward revisions from firms like TD Cowen, Truist, Barclays and an upgrade at Deutsche Bank. These moves reflect analysts’ focus on its refined discount rate, revenue growth outlook, profit margin assumptions and expected future P/E multiple.내러티브 업데이트 • May 13
DVA: Buybacks And Revised Earnings Assumptions Will Confront Emerging GLP-1 Headwinds
DaVita's analyst price target has shifted from $151.71 to $193.71, with analysts pointing to updated assumptions for revenue growth, profit margins and future P/E multiples, along with a series of recent target hikes and an upgrade from major firms as key drivers behind the change. Analyst Commentary Recent Street research on DaVita has been active, with several firms revisiting their models and adjusting targets.내러티브 업데이트 • Apr 28
DVA: Buybacks And Earnings Assumptions Will Shape Future Return Balance
Analysts have raised DaVita's consolidated price target by $30 to $151.71, citing updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent Street research on DaVita has centered on higher price targets and refreshed assumptions around discount rates, revenue outlook, margins and future P/E multiples.내러티브 업데이트 • Apr 07
DVA: Buyback Pace And Long Term Earnings Assumptions Will Shape Future Returns
Analysts raised their DaVita price targets by up to $30, citing updated assumptions for discount rates and long term earnings multiples, while keeping core fair value drivers broadly unchanged. Analyst Commentary Recent research updates around DaVita have focused on recalibrating valuation frameworks rather than shifting the core business thesis.내러티브 업데이트 • Mar 23
DVA: Ongoing Buybacks And Revised P/E Assumptions Will Shape Future Returns
DaVita’s analyst price target has been revised to $151.71, with analysts pointing to updated assumptions around the discount rate and forward P/E as key drivers of the refreshed outlook. Analyst Commentary Recent Street research on DaVita points to a cluster of higher price targets, with several firms revisiting their models around discount rates and forward P/E assumptions.내러티브 업데이트 • Mar 08
DVA: Ongoing Buybacks And Repriced Execution Risk Will Shape Future Returns
Our updated analyst price target for DaVita edges higher by a few dollars to reflect slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E, generally in line with the recent series of upward target revisions from Truist, TD Cowen, UBS and Barclays. Analyst Commentary Bullish Takeaways Bullish analysts raising price targets by US$4 to US$30 signal increased confidence in DaVita's ability to execute against current expectations rather than a complete reset of the story.내러티브 업데이트 • Feb 21
DVA: Buybacks And Richer P/E Assumptions Will Shape Future Return Potential
Analysts have raised their DaVita fair value estimate from $147.75 to $151.71, reflecting updated assumptions on the discount rate, revenue growth, profit margins, and future P/E following a series of recent price target increases from major research firms. Analyst Commentary Recent price target changes from several firms point to a reappraisal of DaVita's risk and reward profile, which feeds directly into the updated fair value estimate.분석 기사 • Feb 06
Even With A 30% Surge, Cautious Investors Are Not Rewarding DaVita Inc.'s (NYSE:DVA) Performance Completely
DaVita Inc. ( NYSE:DVA ) shares have had a really impressive month, gaining 30% after a shaky period beforehand. Not...내러티브 업데이트 • Feb 05
DVA: Updated Cash Returns And Margin Assumptions Will Shape Future Upside Potential
Our DaVita view now reflects a higher fair value estimate of $147.75, up from $143.00. Analysts point to updated assumptions on discount rate, revenue growth, margin profile, and a lower future P/E as key drivers behind the price target revisions across recent Street reports.내러티브 업데이트 • Jan 22
DVA: Share Repurchases And Kidney Research Pipeline Will Support Future Upside
Analysts have kept their fair value estimate for DaVita steady at US$143.00. They cited only small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their outlook.내러티브 업데이트 • Jan 07
DVA: Clinical Research Pipeline And Buybacks Will Support Earnings Despite Reimbursement Headwinds
Analysts have trimmed their price target for DaVita by about $1.50 to $143, reflecting slightly higher discount rate and P/E assumptions while keeping growth and margin expectations broadly in line. What's in the News DaVita plans to unveil six new studies at the American Society of Nephrology's Kidney Week 2025 in Houston, focused on dialysis treatments, middle molecule clearance, access to transplantation and end of life care (Key Developments).내러티브 업데이트 • Dec 20
DVA: Clinical Initiatives And Buybacks Will Support Earnings Despite Reimbursement Headwinds
Analysts modestly raised their price target on DaVita to about $145 per share, reflecting slightly lower discount rate assumptions and a marginally improved long term earnings outlook, while maintaining stable fair value and growth expectations. What's in the News DaVita will unveil six new clinical studies at ASN Kidney Week 2025 in Houston, including an oral presentation on GLP-1 receptor agonist use and its association with lower hospitalization rates in end stage kidney disease patients (company announcement).내러티브 업데이트 • Dec 06
DVA: Hospital Fundamentals Will Support Earnings Amid Tougher Reimbursement Outlook
Analysts have modestly reduced their price target on DaVita to $140 from $145, reflecting increased concern about a more challenging policy and reimbursement environment, despite generally solid hospital fundamentals. Analyst Commentary Analyst sentiment around DaVita remains mixed, with modestly reduced price targets reflecting both confidence in the company’s operational footing and caution about the evolving reimbursement backdrop.내러티브 업데이트 • Nov 22
DVA: Hospital Fundamentals And Resilient Execution Will Drive Steady Performance
DaVita’s analyst price target has been revised downward from $147.13 to $144.50, as analysts cite a cautious outlook due to anticipated policy and reimbursement challenges, despite otherwise steady hospital fundamentals. Analyst Commentary Analysts have offered a range of perspectives on DaVita following the recent adjustment to its price target.내러티브 업데이트 • Nov 03
DVA: Policy Shifts And Operational Recovery Will Shape Outlook In 2025
DaVita's analyst price target has been reduced from $150.50 to $147.13, as analysts cite ongoing concerns over policy headwinds and recent operational challenges that are impacting forecasts. Analyst Commentary Analysts have updated their outlook on DaVita based on recent sector-wide developments and company-specific events.내러티브 업데이트 • Oct 20
Aging Population And AI Will Reshape Dialysis Care
DaVita's analyst price target has been revised downward from $153.50 to $150.50. This change reflects ongoing concerns among analysts about reimbursement challenges and the impact of recent operational disruptions.내러티브 업데이트 • Sep 04
Aging Population And AI Will Reshape Dialysis Care
Analysts have revised their outlook on DaVita to reflect lower treatment growth, reduced revenue per treatment, and ongoing operational challenges stemming from cyberattack disruptions, resulting in a consensus price target that remains unchanged at $153.50. Analyst Commentary Bearish analysts revised down treatment growth expectations due to higher missed treatment rates stemming from cyberattack disruptions.분석 기사 • Aug 05
Investors Aren't Entirely Convinced By DaVita Inc.'s (NYSE:DVA) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Seeking Alpha • Mar 17
The DaVita Dilemma: Flat Patient Enrollment And Lawsuits, Yet An Improvement In Net Income Margin
Summary Between 2016 and 2024, DaVita's revenues grew less proportionally than the U.S. inflation. DVA has experienced difficulty enrolling more patients in its dialysis program, reporting a decline in its patients since 2019. Since 2012, the company has experienced lawsuits, which have cost approximately $1,000 million in payments and have negatively affected its reputation. The net income of DaVita increased by 50.59% between 2017 and 2024. In the last year, the company reported an 11.66% net income margin. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
DaVita: Momentum Could Fade Given High Valuation
Summary DaVita has returned ~60% over the last year, backed by superior earnings growth; however, going forward, I believe earnings growth should slow down. The Company faces headwinds from supply chain issues, higher mortality rates, and increased interest expenses, but tailwinds from lower center closure costs and Latin America acquisitions should more than offset headwinds. DVA stock is currently trading at a premium compared to the historical average. Applying a 14x PE multiple to the 2025 consensus EPS of $11.44, I estimate a fair value of $160 per share, below the current $177. Read the full article on Seeking AlphaSeeking Alpha • Nov 14
DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation
Summary Despite operational success and growth potential, I rate DaVita Inc. a “Hold” due to its high debt, lack of dividend, and current overvaluation. DaVita excels in dialysis services but faces significant risks from debt servicing costs, macroeconomic factors, and potential policy changes. The company's recent financial performance, including a decline in net income and increased debt costs, underscores my conservative valuation approach. I assign DaVita a price target of $130/share, reflecting a cautious outlook on growth and valuation amidst industry and economic uncertainties. Read the full article on Seeking Alpha
새로운 내러티브 • Aug 22
Critical Investments And Policy Changes Propel Healthcare Innovator Towards Brighter Financial Horizons
DaVita's investments in technology and workforce initiatives aim to enhance revenue operations and patient care, contributing to future growth and profitability.주주 수익률
| DVA | US Healthcare | US 시장 | |
|---|---|---|---|
| 7D | 0.9% | 0.03% | -0.7% |
| 1Y | 62.6% | 39.5% | 15.3% |
수익률 대 산업: DVA은 지난 1년 동안 39.5%의 수익을 기록한 US Healthcare 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: DVA은 지난 1년 동안 15.3%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| DVA volatility | |
|---|---|
| DVA Average Weekly Movement | 7.4% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: DVA는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: DVA의 주간 변동성(7%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1994 | 78,000 | Javier Rodriguez | www.davita.com |
는 미국에서 만성 신부전으로 고통받는 환자들을 위한 신장 투석 서비스를 제공합니다. 이 회사는 신장 투석 센터를 운영하고 외래 환자 투석 센터에서 관련 검사실 서비스를 제공합니다. 또한 외래, 병원 입원 및 가정 기반 혈액 투석 투석 서비스를 제공하고, 투석 및 기타 의사가 처방한 ESRD 환자를 위한 일상적인 실험실 검사를 제공하는 임상 실험실을 운영하며, 외래 투석 센터에 관리 및 행정 서비스를 제공합니다.
DaVita Inc. 기초 지표 요약
| DVA 기초 통계 | |
|---|---|
| 시가총액 | US$15.12b |
| 순이익 (TTM) | US$756.42m |
| 매출 (TTM) | US$13.84b |
20.1x
주가수익비율(P/E)1.1x
주가매출비율(P/S)DVA는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| DVA 손익계산서 (TTM) | |
|---|---|
| 매출 | US$13.84b |
| 매출원가 | US$9.35b |
| 총이익 | US$4.49b |
| 기타 비용 | US$3.73b |
| 순이익 | US$756.42m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Aug 04, 2026
| 주당순이익(EPS) | 11.78 |
| 총이익률 | 32.45% |
| 순이익률 | 5.47% |
| 부채/자본 비율 | 996.9% |
DVA의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/27 07:28 |
| 종가 | 2026/07/27 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
DaVita Inc.는 28명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Matthew Gillmor | Baird |
| Sarah James | Barclays |
| Andrew Mok | Barclays |